Teva offers to buy Mylan in $40.1B cash-and-stock deal
Israeli pharmaceutical company Teva has offered to buy Mylan for about $40.1 billion in cash and stock in a deal that would create a powerhouse of generic drug development.
If Teva manages to acquire Mylan under the offer announced Tuesday, it would help Teva secure a more dominant position as it would be taking Mylan off of a growing list of competitors. Teva would also get a competitive edge against rivals such as Sun Pharma, which itself consolidated for a more powerful position when it took a controlling stake of its rival Ranbaxy in 2014.
But Mylan already announced Friday as speculation was swirling about a possible Teva bid that it doubted that regulators would approve such a deal and said it is committed to its current strategy as a stand-alone company.
